Elucid Bioimaging
About Elucid Bioimaging
Elucid Bioimaging is a pioneering AI medical technology company dedicated to providing physicians with advanced imaging analysis software to enhance the diagnosis and management of cardiovascular disease. Their flagship product, PlaqueIQ™, is an FDA-cleared, non-invasive software that objectively quantifies and classifies arterial plaque morphology. Uniquely, PlaqueIQ™ is validated against ground-truth histology, considered the gold standard for plaque characterization, offering a level of precision beyond traditional imaging techniques.
For physicians, Elucid’s technology provides critical, patient-specific insights into plaque composition, including the identification and quantification of high-risk components like lipid-rich necrotic core. This detailed information supports tailored medical guidance, helps assess the risk of future cardiac events such as heart attack and stroke, and informs personalized treatment pathways. The software integrates with standard CT angiography (CTA) scanners and is designed to aid in timely clinical decision-making by providing actionable reports and 3D visualizations of vessel structure and plaque characteristics.
Elucid’s offerings aim to revolutionize vascular diagnostics by enabling a more precise view of atherosclerosis, moving beyond population-based risk assessments to disease-specific insights. The company is also developing FFRct estimation software, which derives fractional flow reserve estimates from CTA-derived plaque and vessel metrics to assess lesion-specific ischemia non-invasively. Recent developments include broad reimbursement for quantitative coronary plaque analysis and the launch of PlaqueIQ™ for carotid arteries, further expanding its clinical utility.
Focus Areas
Business Intelligence
| Key Investors | Elevage Medical Technologies, Unorthodox Ventures, Aphelion Capital, Biovision Ventures, Philips Ventures, MedTex Ventures, IAG Capital, Bold Brain Ventures, BlueStone Venture Partners, Checkmate Capital, Global Health Impact Funds, University of Michigan – Wolverine Venture Fund, Willamette Valley Capital LLC, Angel Physicians Fund, National Science Foundation |
| Partnerships | United Healthcare (coverage for PlaqueIQ), Centers for Medicare & Medicaid Services (CMS) (reimbursement for PlaqueIQ) |
| Acquisitions | None |
| Technology | AI-powered imaging analysis software, machine learning algorithms, ground-truth histology validated, CT angiography (CTA) analysis, 3D modeling, cloud-native (implied by software delivery and data processing) |
| FDA Clearances | 1 cleared products (estimated) |
What Physicians Need to Know
Elucid Bioimaging's technology offers physicians a transformative approach to cardiovascular disease management. By providing objective, quantitative, and histology-validated insights into plaque composition and morphology from routine CT angiography, you can move beyond traditional stenosis-based assessments. This enables more precise risk stratification, allowing for earlier identification of high-risk plaques (e.g., lipid-rich necrotic core) and the tailoring of personalized treatment strategies for stroke and heart attack prevention. The non-invasive nature of the analysis, coupled with its potential for FFRct estimation, streamlines workflow and provides critical information for guiding medical therapy versus intervention. The broad reimbursement coverage further supports the integration of this advanced diagnostic tool into clinical practice, ultimately leading to more informed decision-making and improved patient outcomes.
Elucid's technology is designed for seamless integration into existing clinical workflows, supporting DICOM integration and interoperability with PACS and EMR systems. Deployment options include both cloud and on-premise secure solutions, ensuring data protection aligned with SOC 2 and HIPAA standards.
Reviews & Opinions
Videos
News, demos, and interviews about Elucid Bioimaging.
Videos load interactively. If none appear, search YouTube for Elucid Bioimaging →
Press & Coverage
Frequently Asked Questions
Comparisons
Related Companies
QuickIntell is an AI-first healthcare technology company dedicated to transforming healthcare operations for physicians and healthcare providers. The company leverages advanced AI agents, including Computer Vision, Machine Learning, Optical Character Recognition (OCR), and Natural Language Processing (NLP), to streamline administrative workflows and enhance Revenue Cycle Management (RCM). QuickIntell’s solutions are designed to reduce administrative burden, […]
Ease Tax Relief, founded in 2016, is a tax relief and resolution company based in Harleysville, PA. The company specializes in helping individuals and small businesses resolve issues with the IRS, offering services such as Offer in Compromise, Partial Pay Installment Agreements, Payment Plans, and Penalty Reduction. Owned and operated by Zheng Yang, a CPA […]
CAIMed, the Lower Saxony Center for Artificial Intelligence and Causal Methods in Medicine, is a research institution dedicated to advancing personalized healthcare through innovative AI and causal methodologies. The center aims to address widespread diseases such as cancer, cardiovascular diseases, and infections by linking research data, clinical data, and patient care data. This integrated approach, […]
Autoderm is a health technology company that provides a CE-marked AI dermatology screening API designed to analyze smartphone photos for various skin conditions. The company’s AI models are trained on a proprietary database of amateur smartphone images of skin diseases and are accessible via an API that can be integrated into various platforms, including electronic […]
OCTA is an AI-powered finance automation platform that aims to streamline financial operations and accelerate cash flow for businesses, particularly SMEs and enterprises in the Middle East, with a strong presence in the UAE and Saudi Arabia. The platform utilizes AI agents to automate tasks across the entire contract-to-cash cycle, including contract creation, e-signing, invoicing, […]
Skin Analytics is a British health technology company dedicated to the early and accurate diagnosis of skin cancer, aiming to reduce mortality from the disease. They achieve this through their flagship product, DERM, an AI-powered medical device. DERM is designed to provide dermatologist-quality skin cancer assessments, making them more accessible and reducing the burden on […]